Clinical trial · Interventional
REmote Symptom COllection to improVE postopeRative Care
NCT06190730CI-TRIAL-00088076RECOVERrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
There are vulnerabilities in post-discharge care transition for patients after undergoing resection of malignant gastrointestinal tumors. This study aims to investigate the possibility of utilizing Voice-Assisted Remote Symptom Monitoring System (VARSMS) to alleviate some of these challenges.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointestinal Cancer | Malignant Digestive System Neoplasm | ALIAS | 0.90 |
| Gastrointestinal Surgery | — | UNRESOLVED | — |
| Gastrointestinal Tumor | Digestive System Neoplasm | ALIAS | 0.90 |
| Gastrointestinal Tumor Surgery | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Voice-Assisted Remote Symptom Monitoring System (VARSMS) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Control
- description
- Besides the consent process, subjects in this arm will have no other research-specific activities until after 40 days after the surgery for an exit interview.
- type
- EXPERIMENTAL
- label
- Voice-Assisted Remote Symptom Monitoring System (VARSMS) group
- description
- Subjects in this group will be issued the device, to be activated 1 day after discharge. The device will administer a set of questions daily.
- interventionNames
- Other: Voice-Assisted Remote Symptom Monitoring System (VARSMS)
Primary outcomes (1)
- measure
- Custom questionnaire based on NCI PRO CTCAE (National Cancer Institute- Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events)
- timeFrame
- 40 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria 1. At least 18 years old. Ages of subjects \>89 will simply be reported as \>90. 2. Scheduled for a GI surgery for management of a tumor in a participating hospital. 3. Fluent in oral and written English. 4. Has consistent and continued full access to an operational Wi-Fi for the duration of the study. Exclusion criteria 1. Unable to provide informed consent. 2. Not willing to commit to regular participation in the study to include daily use (40 days) of the study application. 3. Life expectancy of less than 60 days. 4. In the opinion of the investigator, participation in this study is contraindicated.
References
Publications (0)
Data not yet available
No reference posted for this study.